| 词条 | Otenabant |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 417842381 | IUPAC_name = 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide | image = Otenabant.svg | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 686344-29-6 | ATC_prefix = none | ATC_suffix = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|changed|FDA}} | UNII = J8211Y53EF | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D09362 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 562668 | PubChem = 10052040 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 8227602 | chemical_formula = | C=25 | H=25 | Cl=2 | N=7 | O=1 | molecular_weight = 510.4 g/mol | smiles = CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35) | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = UNAZAADNBYXMIV-UHFFFAOYSA-N }}Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3] See also
References1. ^{{Citation |last= Kim |first= M.|title= Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist |journal= Tetrahedron |volume= 64 |issue= 48 |pages= 10802–10809 |year= 2008 |url=http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6THR-4TJ1HGJ-9-2&_cdi=5289&_user=713789&_orig=search&_coverDate=11%2F24%2F2008&_sk=999359951&view=c&wchp=dGLbVzb-zSkWA&md5=2e8fe6fab24adb1087bd17bbcd3544a7&ie=/sdarticle.pdf |doi= 10.1016/j.tet.2008.09.057 |display-authors=etal}} {{Anorectics}}{{Cannabinoids}}{{Cannabinoidergics}}{{cannabinoid-stub}}2. ^Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. {{PMID|18047036}} 3. ^http://www.pfizer.com 8 : Cannabinoids|Purines|Piperidines|Carboxamides|Chloroarenes|Pfizer|Pfizer products|CB1 receptor antagonists |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。